Compare Marriott International Inc (MAR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marriott International Inc vs Pfizer Inc — how do they compare? Marriott International Inc trades at $360.95 (market cap $92.96B), while Pfizer Inc trades at $27.83 (market cap $159.59B). The key difference: Pfizer Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Marriott International Inc for 164 Days and Pfizer Inc for 158 Days on average.
| MAR | PFE | |
|---|---|---|
Market Cap | $92.96B | $159.59B |
Volume | 1,173,633 | 30,937,010 |
Sector | Consumer Cyclical | Health |
52-Week High | $402.54 | $29.02 |
52-Week Low | $259.04 | $23.67 |
Typical Hold Time | 164 Days | 158 Days |
Enterprise Value | $110.28B | $211.09B |
Dividend Yield | 0.82% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marriott International (MAR) trades at $356.50, down 1.32% on the day, with a bullish technical signal from moving averages and support near $354. Revenue grew to $26.19B in 2025, with a net income margin of 9.62%, though the P/E of 36.9 suggests a premium valuation. Recent earnings beat expectations in Q1 and Q2 2026, and the company announced a quarterly dividend of $0.73 per share payable in September 2026. Analyst consensus is a Buy with a $386.71 price target, indicating potential upside.
The outlook for MAR is positive, supported by strong travel demand and strategic partnerships, but risks include high debt levels and sensitivity to economic cycles. With institutional interest mixed and a neutral sentiment from oscillators, the stock offers growth potential tempered by valuation concerns and macroeconomic headwinds.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
